6 Real-world Adherence and Persistence With Palbociclib Treatment Among Insured Patients With HR+/HER2– Metastatic Breast Cancer in the United States

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement39th Annual Miami Breast Cancer Conference® - Abstracts
Volume 36
Issue suppl 3
Pages: 10

Background/Significance

Palbociclib (Ibrance), the first oral cyclin-dependent kinase inhibitor, is standard care for hormone receptor–positive (HR+), HER2- advanced or metastatic breast cancer (mBC). Palbociclib adherence and persistence are necessary to achieve optimal clinical outcomes in patients treated in
real-world settings.


Materials and Methods

This was a retrospective cohort study of insured adults in the Optum Research Database, an administrative health care claims database capturing about 20% of commercial and Medicare Advantage Part D enrollees in the United States. Adults diagnosed with mBC between February 2015 and December 2019 who initiated palbociclib in the first-line (1L) setting were selected for analysis. The index date was the first fill date of palbociclib before or anytime after the mBC diagnosis. Continuous enrollment 12 or more months pre- and 1 or more months post index was required. Palbociclib treatment was evaluated over the variable follow-up period. Medication possession ratio (MPR) was calculated as palbociclib days’ supply between the first and last fill divided by the total time treated. MPR of 80% or more was considered adherent. Palbociclib discontinuation was defined by the occurrence of a 60- or 90-day gap in days’ supply, adjusted for inpatient stays during which time medication was assumed to be supplied by the facility. Persistence was calculated as the time to palbociclib discontinuation using Kaplan-Meier methods over variable follow-up.



Results

One thousand sixty-six patients initiated 1L palbociclib, with 811 patients receiving palbociclib with aromatase inhibitors (P+AI) and 255 patients receiving palbociclib with fulvestrant (P+F). Mean follow-up time was 17 (P+AI) and 16 months (P+F). Mean age was 67 years for P+F and 66 years for P+AI. Overall, 79.9% of patients were adherent; mean MPR was 0.88 (median, 0.94) within each group. During the variable follow-up period, 41.3% of patients receiving P+AI and 45.9% receiving P+F discontinued palbociclib. Among those who discontinued, 23.9% and 21.4% discontinued within the first 3 months, respectively. Median time to discontinuation was 19.9 months (P+AI) and
15.2 months (P+F); 59.1% receiving P+F and 68.7% receiving P+AI remained on palbociclib at 12 months post index (90-day gap).


Conclusions

This analysis suggests most patients are well adherent with 1L palbociclib and persist on therapy. Further research is needed to understand reasons for early discontinuation in real-world practice.

Author Affiliations:

Nicole M. Engel-Nitz,1 Samantha M. Kurosky,2 Mary Grace Johnson,1 Michael P. Johnson, Xianchen Liu

1Optum, Inc

2Pfizer Inc

Articles in this issue

15 COVID-19 Disease Course in Immunocompetent and Immunocompromised Patients  in a Breast Cancer Registry
15 COVID-19 Disease Course in Immunocompetent and Immunocompromised Patients in a Breast Cancer Registry
37 The Routine Use of Bioimpedance Spectroscopy Measurements in the Clinic as a Surrogate for Bone Mineral Content in Oncology Patients: Practical Application of the SOZO Device
37 The Routine Use of Bioimpedance Spectroscopy Measurements in the Clinic as a Surrogate for Bone Mineral Content in Oncology Patients: Practical Application of the SOZO Device
18 Psychosocial Wellbeing and Health Care Resource Utilization Among Patients With Breast Cancer During COVID-19
18 Psychosocial Wellbeing and Health Care Resource Utilization Among Patients With Breast Cancer During COVID-19
43 Early Detection of Breast Cancer–Related Lymphedema: Accuracy of Indocyanine Green Lymphography Compared With Bioimpedance Spectroscopy  and Symptoms
43 Early Detection of Breast Cancer–Related Lymphedema: Accuracy of Indocyanine Green Lymphography Compared With Bioimpedance Spectroscopy and Symptoms
3 Frequency of Germline Variants in Breast Cancer Predisposing Genes: Genetic Background of Brazilian Women With Breast Cancer
3 Frequency of Germline Variants in Breast Cancer Predisposing Genes: Genetic Background of Brazilian Women With Breast Cancer
44 Implementation of a Novel Radiopaque Filament Marker at a Single Breast Cancer Surgery Center
44 Implementation of a Novel Radiopaque Filament Marker at a Single Breast Cancer Surgery Center
39TiP The PREDICT Registry: A Prospective Registry Study to Evaluate the Effect of a Predictive Assay on Treatment Decisions in Patients withDCIS Following Breast Conserving Therapy
39TiP The PREDICT Registry: A Prospective Registry Study to Evaluate the Effect of a Predictive Assay on Treatment Decisions in Patients withDCIS Following Breast Conserving Therapy
38 Clinicopathological Risk Factors, Poorly Stratified Baseline Risk, and RT Benefit Compared to DCISionRT in Patients With Ductal Carcinoma in Situ
38 Clinicopathological Risk Factors, Poorly Stratified Baseline Risk, and RT Benefit Compared to DCISionRT in Patients With Ductal Carcinoma in Situ
28 Case Series: Imaging Appearance of Non–Breast Cancer Solid Masses in the Male Breast
28 Case Series: Imaging Appearance of Non–Breast Cancer Solid Masses in the Male Breast
20 Evaluating Number, Age, and Radiographic BIRADS of Patients Visiting Mammography Unit in Baghdad, Iraq, in 2019, 2020, and 2021: A Retrospective Study
20 Evaluating Number, Age, and Radiographic BIRADS of Patients Visiting Mammography Unit in Baghdad, Iraq, in 2019, 2020, and 2021: A Retrospective Study
5 Feasibility of WF-OCT as an Adjunct to Intraoperative Specimen X-ray for Breast Conservation Surgical Specimens
5 Feasibility of WF-OCT as an Adjunct to Intraoperative Specimen X-ray for Breast Conservation Surgical Specimens
41 A Single-Centre Report on the Upgrade Rate of Complex Sclerosing Lesions of the Breast
41 A Single-Centre Report on the Upgrade Rate of Complex Sclerosing Lesions of the Breast
45 The Informed Consent Experience for Breast Cancer Surgery and Its Association With Patient Satisfaction
45 The Informed Consent Experience for Breast Cancer Surgery and Its Association With Patient Satisfaction
29 The Effect of Personality Type on Satisfaction With Information Exchange in Breast Cancer Patients
29 The Effect of Personality Type on Satisfaction With Information Exchange in Breast Cancer Patients
36 Are Positive Margins in DCIS a True Indication of Inadequate Surgery?
36 Are Positive Margins in DCIS a True Indication of Inadequate Surgery?
Related Content